Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Tomlinson, I.P.M.

Search results

  • RSS Feed
(1 - 8 of 8)
Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Gool, I.C. van; Rayner, E.; Osse, E.M.; Nout, R.A.; Creutzberg, C.L.; Tomlinson, I.P.M.; ... ; Drost, M. 2018
Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Article / Letter to editor
open access
Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk
Guo, X.Y.; Long, J.R.; Zeng, C.J.; Michailidou, K.; Ghoussaini, M.; Bolla, M.K.; ... ; kConFab Investigators 2015
Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk
Article / Letter to editor
metadata only
Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer
Timofeeva, M.N.; Kinnersley ben; Farrington, S.M.; Whiffin, N.; Palles, C.; Svinti, V.; ... ; Houlston, R.S. 2015
Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer
Article / Letter to editor
open access
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Gool, I.C. van; Eggink, F.A.; Freeman-Mills, L.; Stelloo, E.; Marchi, E.; Bruyn, M. de; ... ; Church, D.N. 2015
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Article / Letter to editor
metadata only
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
Church, D.N.; Stelloo, E.; Nout, R.A.; Valtcheva, N.; Depreeuw, J.; Haar, N. ter; ... ; Bosse, T. 2015
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
Article / Letter to editor
metadata only
PROGNOSTIC SIGNIFICANCE OF POLE EXONUCLEASE DOMAIN MUTATION IN EARLY STAGE ENDOMETRIAL CANCER
Church, D.; Stelloo, E.; Nout, R.A.; Valtcheva, N.; Depreeuw, J.; Haar, N. ter; ... ; Bosse, T. 2014
PROGNOSTIC SIGNIFICANCE OF POLE EXONUCLEASE DOMAIN MUTATION IN EARLY STAGE ENDOMETRIAL CANCER
Article / Letter to editor
metadata only
Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13
Spain, S.L.; Carvajal-Carmona, L.G.; Howarth, K.M.; Jones, A.M.; Su, Z.; Cazier, J.B.; ... ; Tomlinson, I.P.M. 2012
Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13
Article / Letter to editor
metadata only
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer
Tomlinson, I.P.M.; Dunlop, M.; Campbell, H.; Zanke, B.; Gallinger, S.; Hudson, T.; ... ; Houlston, R.S. 2010
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer
Article / Letter to editor
metadata only
It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in... Show moreIt is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT. British Journal of Cancer (2010) 102, 447-454. doi:10.1038/sj.bjc.6605338 www.bjcancer.com Published online 17 November 2009 (C) 2010 Cancer Research UK Show less